N-(2-吡啶甲基)哌嗪-1-乙胺 | 6957-14-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-(2-吡啶甲基)哌嗪-1-乙胺
• 英文名称: N-(2-Pyridylmethyl)piperazine-1-ethylamine
• 英文别名: 2-piperazin-1-yl-N-(pyridin-2-ylmethyl)ethanamine
• CAS: 6957-14-8
• 化学式: C₁₂H₂₀N₄
• mdl: MFCD00085508
• 分子量: 220.31
• InChiKey: KRQSKMDJMSKNLA-UHFFFAOYSA-N

物化性质

• 沸点：
  360.9±32.0 °C(Predicted)
• 密度：
  1.047±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.583
• 拓扑面积：
  40.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Novel antibacterial agents
  申请人：Christensen G. Burton

  公开号：US20070134729A1

  公开（公告）日：2007-06-14

  This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

  本发明涉及一种新型多结合化合物（药剂），其为抗菌剂。该发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个单价（即未连接的）配体具有与细胞壁生物合成和代谢中的酶、合成细菌细胞壁和/或细菌细胞表面的前体有结合能力，从而干扰细胞壁的合成和/或代谢。特别地，本发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个配体具有能够结合青霉素结合蛋白、横向肽酶酶、横向肽酶酶底物、β-内酰胺酶、青霉素酶、头孢菌素酶、横向转移酶酶或横向转移酶酶底物的配体结构域。优选地，配体选自β-内酰胺类或糖肽类抗菌剂。
• Support-fixed bleaching catalyst complex compounds suitable as catalysts for peroxygen compounds
  申请人：——

  公开号：US20040266641A1

  公开（公告）日：2004-12-30

  The present invention relates to support-fixed bleaching catalyst(s)suitable or the catalysis of peroxide compounds, characterized in that the support-fixed bleaching catalyst(s) is/are covalently bonded to a support by means of at least one organic ligand of the bleaching catalyst. The bleaching catalyst(s) form(s) a complex with at least on transition metal. The invention further relates to support-fixed bleaching catalysts for the catalysis of peroxide compounds, where at least one ligand, covalently bonded to a support, is a transition-metal-free ligand, which chelates with transition metal, derived from another source, preferably from the bleaching composition and/or added water and thus forms the complex with a transition metal.

  本发明涉及适用于过氧化物催化的支撑固定漂白催化剂，其特征在于通过漂白催化剂的至少一个有机配体与支撑物共价键合而将支撑固定漂白催化剂共价键合到支撑物上。漂白催化剂与至少一种过渡金属形成复合物。本发明还涉及适用于过氧化物催化的支撑固定漂白催化剂，其中至少一个共价键合到支撑物上的配体是无过渡金属配体，它与来自另一来源的过渡金属螯合，优选地来自漂白组合物和/或加入的水，并因此形成与过渡金属的复合物。
• Beta2-Adrenergic Receptor Agonists
  申请人：Moran Edmund J.

  公开号：US20080269344A1

  公开（公告）日：2008-10-30

  Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及多结合化合物，其是β2肾上腺素能受体激动剂，可用于治疗和预防哮喘、支气管炎等呼吸系统疾病。它们还可用于治疗神经系统损伤和早产。
• Beta2-adrenergic receptor agonists
  申请人：Moran J. Edmund

  公开号：US20070179179A1

  公开（公告）日：2007-08-02

  Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及多重结合化合物，其为β2肾上腺素能受体激动剂，可用于治疗和预防哮喘、支气管炎等呼吸系统疾病。它们还可用于治疗神经系统损伤和早产。
• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。